• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Brexit means little for biotech stocks, analyst says

    Brexit means little for biotech stocks, analyst says

  2. Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

    Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

  3. Health-care stocks rally as Medicare cost-cutting not triggered

    Health-care stocks rally as Medicare cost-cutting not triggered

  4. Ulcerative Colitis - Pipeline Review, H1 2016 - Key Players Include Amgen, Gilead Sciences & Celgene Corporation - Research and Markets

    Ulcerative Colitis - Pipeline Review, H1 2016 - Key Players Include Amgen, Gilead Sciences & Celgene Corporation - Research and Markets

  5. Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association

    Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association

  6. Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association

    Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association

  7. Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID® Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma

    Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID® Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma

  8. Data Presented at ASCO 2016 Builds upon Foundation of Abraxane® Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer

    Data Presented at ASCO 2016 Builds upon Foundation of Abraxane® Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer

  9. Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability

    Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability

  10. Juno Therapeutics’ Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL

    Juno Therapeutics’ Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.